Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials

International Journal of Cardiology

Volumn 181, Issue , 2015, Pages 331-339

  Bulluck, Heerajnarain ^a   Kwok, Chun Shing ^b   Ryding, Alisdair D ^c   Loke, Yoon K ^c,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Acute coronary syndrome; Drug eluting stent; Dual antiplatelet treatment; Duration of therapy; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; TICAGRELOR; TICLOPIDINE; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM CARE; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHORT COURSE THERAPY; STENT THROMBOSIS; TREATMENT DURATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPARATIVE STUDY; CORONARY DISEASE; HEMORRHAGE; STANDARDS; THROMBOSIS; TREATMENT OUTCOME; TRENDS;

CORONARY DISEASE; DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOSIS; TREATMENT OUTCOME;

EID: 84947201471     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.12.037     Document Type: Article

References (42)

1. I. Iakovou, T. Schmidt, E. Bonizzoni, L. Ge, G.M. Sangiorgi, G. Stankovic, F. Airoldi, A. Chieffo, M. Montorfano, M. Carlino, I. Michev, N. Corvaja, C. Briguori, U. Gerckens, E. Grube, and A. Colombo Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
2. M. Pfisterer, H.P. Brunner-La Rocca, P.T. Buser, P. Rickenbacher, P. Hunziker, C. Mueller, R. Jeger, F. Bader, S. Osswald, C. Kaiser, and B.-L. Investigators Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J. Am. Coll. Cardiol. 48 2006 2584 2591
3. A. Jeremias, B. Sylvia, J. Bridges, A.J. Kirtane, B. Bigelow, D.S. Pinto, K.K. Ho, D.J. Cohen, L.A. Garcia, D.E. Cutlip, and J.P. Carrozza Jr. Stent thrombosis after successful sirolimus-eluting stent implantation Circulation 109 2004 1930 1932
4. G. Sarno, B. Lagerqvist, O. Frobert, J. Nilsson, G. Olivecrona, E. Omerovic, N. Saleh, D. Venetzanos, and S. James Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR) Eur. Heart J. 33 2012 606 613
5. B.J. Doyle, C.S. Rihal, D.A. Gastineau, and D.R. Holmes Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice J. Am. Coll. Cardiol. 53 2009 2019 2027
6. A.D. Bowry, M.A. Brookhart, and N.K. Choudhry Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events Am. J. Cardiol. 101 2008 960 966
7. P.B. Berger, D.L. Bhatt, V. Fuster, P.G. Steg, K.A. Fox, M. Shao, D.M. Brennan, W. Hacke, G. Montalescot, S.R. Steinhubl, and E.J. Topol Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial Circulation 121 2010 2575 2583
8. D.W. Park, S.W. Park, K.H. Park, B.K. Lee, Y.H. Kim, C.W. Lee, M.K. Hong, J.J. Kim, and S.J. Park Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up Am. J. Cardiol. 98 2006 352 356
9. E.L. Eisenstein, K.J. Anstrom, D.F. Kong, L.K. Shaw, R.H. Tuttle, D.B. Mark, J.M. Kramer, R.A. Harrington, D.B. Matchar, D.E. Kandzari, E.D. Peterson, K.A. Schulman, and R.M. Califf Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation JAMA 297 2007 159 168
10. G.N. Levine, E.R. Bates, J.C. Blankenship, S.R. Bailey, J.A. Bittl, B. Cercek, C.E. Chambers, S.G. Ellis, R.A. Guyton, S.M. Hollenberg, U.N. Khot, R.A. Lange, L. Mauri, R. Mehran, I.D. Moussa, D. Mukherjee, B.K. Nallamothu, and H.H. Ting 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions Circulation 124 2011 e574 e651
11. S. Windecker, P. Kolh, F. Alfonso, J.P. Collet, J. Cremer, V. Falk, G. Filippatos, C. Hamm, S.J. Head, P. Juni, A.P. Kappetein, A. Kastrati, J. Knuuti, U. Landmesser, G. Laufer, F.J. Neumann, D.J. Richter, P. Schauerte, M. Sousa Uva, G.G. Stefanini, D.P. Taggart, L. Torracca, M. Valgimigli, W. Wijns, and A. Witkowski 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) EuroIntervention 2014 10.4244/EIJY14M09-01
12. C.S. Kwok, H. Bulluck, A.D. Ryding, and Y.K. Loke Benefits and harms of extending the duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents: a meta-analysis Sci. World J. 2014 2014 16
13. F. Feres, R.A. Costa, A. Abizaid, M.B. Leon, J.A. Marin-Neto, R.V. Botelho, S.B. King III, M. Negoita, M. Liu, J.E. de Paula, J.A. Mangione, G.X. Meireles, H.J. Castello Jr., E.L. Nicolela Jr., M.A. Perin, F.S. Devito, A. Labrunie, D. Salvadori Jr., M. Gusmao, R. Staico, J.R. Costa Jr., J.P. de Castro, A.S. Abizaid, and D.L. Bhatt Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
14. C.W. Lee, J.M. Ahn, D.W. Park, S.J. Kang, S.W. Lee, Y.H. Kim, S.W. Park, S. Han, S.G. Lee, I.W. Seong, S.W. Rha, M.H. Jeong, D.S. Lim, J.H. Yoon, S.H. Hur, Y.S. Choi, J.Y. Yang, N.H. Lee, H.S. Kim, B.K. Lee, K.S. Kim, S.U. Lee, J.K. Chae, S.S. Cheong, I.W. Suh, H.S. Park, D.Y. Nah, D.S. Jeon, K.B. Seung, K. Lee, J.S. Jang, and S.J. Park Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial Circulation 129 2014 304 312
15. J.P. Collet, J. Silvain, O. Barthelemy, G. Range, G. Cayla, E. Van Belle, T. Cuisset, S. Elhadad, F. Schiele, N. Lhoest, P. Ohlmann, D. Carrie, H. Rousseau, P. Aubry, J. Monsegu, P. Sabouret, S.A. O'Connor, J. Abtan, M. Kerneis, C. Saint-Etienne, F. Beygui, E. Vicaut, G. Montalescot for the ARCTIC investigators Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Lancet 384 2014 1577 1585
16. A. Colombo, A. Chieffo, A. Frasheri, R. Garbo, M. Masotti, N. Salvatella, J.F. Oteo Dominguez, L. Steffanon, G. Tarantini, P. Presbitero, A. Menozzi, E. Pucci, J. Mauri, B.M. Cesana, G. Giustino, and G. Sardella Second generation drug-eluting stents implantation followed by six versus twelve-month-dual antiplatelet therapy-the SECURITY Randomized Clinical Trial J. Am. Coll. Cardiol. 64 2014 2086 2097
17. http://hiru.mcmaster.ca/hiru/HIRU-Hedges-EMBASE-Strategies.aspx and http://hiru.mcmaster.ca/hiru/HIRU-Hedges-MEDLINE-Strategies.aspx.
18. J.P. Higgins, and AD Chapter 8: assessing risk of bias in included studies The Cochrane Collaboration 2008
19. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, J. Savovic, K.F. Schulz, L. Weeks, J.A. Sterne, Cochrane Bias Methods G, and Cochrane Statistical Methods G The Cochrane collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
20. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J. Clin. Epidemiol. 50 1997 683 691
21. Indirect treatment comparison [computer program] 2009 Canadian Agency for Drugs and Technologies in Health Ottawa (computer program, http://www.cadth.ca/index.php/en/itc-user-guide)
22. F. Song, D.G. Altman, A.M. Glenny, and J.J. Deeks Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses BMJ 326 2003 472
23. H. Kim, L. Gurrin, Z. Ademi, and D. Liew Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data Br. J. Clin. Pharmacol. 77 2014 116 121
24. S.J. Park, D.W. Park, Y.H. Kim, S.J. Kang, S.W. Lee, C.W. Lee, K.H. Han, S.W. Park, S.C. Yun, S.G. Lee, S.W. Rha, I.W. Seong, M.H. Jeong, S.H. Hur, N.H. Lee, J. Yoon, J.Y. Yang, B.K. Lee, Y.J. Choi, W.S. Chung, D.S. Lim, S.S. Cheong, K.S. Kim, J.K. Chae, D.Y. Nah, D.S. Jeon, K.B. Seung, J.S. Jang, H.S. Park, and K. Lee Duration of dual antiplatelet therapy after implantation of drug-eluting stents N. Engl. J. Med. 362 2010 1374 1382
25. T. Hu, and H.-C. Wang Duration of dual antiplatelet therapy and outcomes after left main percutaneous coronary intervention Heart 98 2012 E209
26. M. Valgimigli, S.J. Park, H.S. Kim, K.W. Park, D.W. Park, P. Tricoci, and G. Ferrante Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials Int. J. Cardiol. 168 2013 2579 2587
27. S. Cassese, R.A. Byrne, T. Tada, S. Pinieck, M. Joner, T. Ibrahim, L.A. King, M. Fusaro, K.L. Laugwitz, and A. Kastrati Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography Heart 100 2014 153 159
28. L. Raber, M. Magro, G.G. Stefanini, B. Kalesan, R.T. van Domburg, Y. Onuma, P. Wenaweser, J. Daemen, B. Meier, P. Juni, P.W. Serruys, and S. Windecker Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study Circulation 125 2012 1110 1121
29. S. Bangalore, S. Kumar, M. Fusaro, N. Amoroso, M.J. Attubato, F. Feit, D.L. Bhatt, and J. Slater Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2012 2873 2891
30. H.C. Gwon, J.Y. Hahn, K.W. Park, Y.B. Song, I.H. Chae, D.S. Lim, K.R. Han, J.H. Choi, S.H. Choi, H.J. Kang, B.K. Koo, T. Ahn, J.H. Yoon, M.H. Jeong, T.J. Hong, W.Y. Chung, Y.J. Choi, S.H. Hur, H.M. Kwon, D.W. Jeon, B.O. Kim, S.H. Park, N.H. Lee, H.K. Jeon, Y. Jang, and H.S. Kim Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Circulation 125 2012 505 513
31. M. Joner, A.V. Finn, A. Farb, E.K. Mont, F.D. Kolodgie, E. Ladich, R. Kutys, K. Skorija, H.K. Gold, and R. Virmani Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J. Am. Coll. Cardiol. 48 2006 193 202
32. A.J. Kirtane, and G.W. Stone How to minimize stent thrombosis Circulation 124 2011 1283 1287
33. T. Zhang, L. Shen, L. Hu, and B. He Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis J. Clin. Pharmacol. 53 2013 345 351
34. M. Liu, J. Chen, D. Huang, J. Ke, W. Tang, and W. Wu Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a meta-analysis of three randomized controlled trials J. Cardiovasc. Pharmacol. 64 2014 41 46
35. S. Cassese, R.A. Byrne, T. Tada, L.A. King, and A. Kastrati Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials Eur. Heart J. 33 2012 3078 3087
36. B.K. Kim, M.K. Hong, D.H. Shin, C.M. Nam, J.S. Kim, Y.G. Ko, D. Choi, T.S. Kang, B.E. Park, W.C. Kang, S.H. Lee, J.H. Yoon, B.K. Hong, H.M. Kwon, Y. Jang, and R. Investigators A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J. Am. Coll. Cardiol. 60 2012 1340 1348
37. M. Valgimigli, G. Campo, M. Monti, P. Vranckx, G. Percoco, C. Tumscitz, F. Castriota, F. Colombo, M. Tebaldi, G. Fuca, M. Kubbajeh, E. Cangiano, M. Minarelli, A. Scalone, C. Cavazza, A. Frangione, M. Borghesi, J. Marchesini, G. Parrinello, R. Ferrari, and Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study I Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
38. S. Silber, A.J. Kirtane, J.A. Belardi, M. Liu, S. Brar, M. Rothman, and S. Windecker Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation Eur. Heart J. 35 2014 1949 1956
39. F. D'Ascenzo, F. Colombo, U. Barbero, C. Moretti, P. Omede, M.J. Reed, G. Tarantini, G. Frati, J.J. DIN, G. Biondi Zoccai, and F. Gaita Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention: systematic review and meta-analysis J. Interv. Cardiol. 27 2014 233 241
40. L. Mauri, D.J. Kereiakes, S.L. Normand, S.D. Wiviott, D.J. Cohen, D.R. Holmes, S. Bangalore, D.E. Cutlip, M. Pencina, and J.M. Massaro Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions Am. Heart J. 160 2010 1035 1041 (1041.e1)
41. R.A. Byrne, S. Schulz, J. Mehilli, R. Iijima, S. Massberg, F.J. Neumann, J.M. ten Berg, A. Schomig, A. Kastrati, and Intracoronary S, Antithrombotic Regimen S and Investigators EFoSMDATAD-ES Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study Am. Heart J. 157 2009 620 624 (e2)
42. G. Helft, C. Le Feuvre, J.L. Georges, D. Carrie, F. Leclercq, H. Eltchaninoff, A. Furber, F. Prunier, L. Sebagh, S. Cattan, G. Cayla, E. Vicaut, and J.P. Metzger Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial Trials 14 2013 56